Saxagliptin (Onglyza®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000601
English
Authors' recommendations:
Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with insulin (with or without metformin) when this regimen alone with diet and exercise does not provide adequate glycaemic control.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=195435&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Drug Therapy, Combination
- Dipeptidyl-Peptidase IV Inhibitors
- Incretins
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.